Dr. Patrizia Carrieri is a researcher at the French National Institute of Health and Medical research (INSERM). She has a background in methods for epidemiologic research. Her research interests focus on access to care and prevention of HIV and HCV in people who use drugs (PWUD).
Dr. Carrieri’s areas of interest concern the effects of buprenorphine and methadone treatment on HIV and HCV outcomes and the identification of novel models of care and interventions to expand access to HIV and HCV prevention for PWUD in the community and in prison. She has expertise in large longitudinal behavioral studies concerning people living with HIV and/or HCV. Dr. Carrieri was the principal investigator of the MANIF 2000 cohort study on HIV-infected drug users, which documented the positive impact of opioid substitution treatments (methadone and buprenorphine) on the reduction of risk behaviours, on virological response and on adherence to antiretroviral therapy among this vulnerable population. Dr. Carrieri is currently the scientific director of a national non-inferiority randomized trial evaluating long-term outcomes of methadone induction in primary care (ANRS Methaville).